Literature DB >> 26143313

Efficacy and safety of nebulized morphine given at 2 different doses compared to IV titrated morphine in trauma pain.

Mohamed Habib Grissa1, Hamdi Boubaker1, Asma Zorgati2, Kaouthar Beltaïef1, Wafa Zhani3, Mohamed Amine Msolli3, Nasri Bzeouich3, Wahid Bouida1, Riadh Boukef4, Semir Nouira5.   

Abstract

BACKGROUND: Our aim was to compare the efficacy and safety of intravenous (IV) titrated morphine with nebulized morphine given at 2 different doses in severe traumatic pain.
METHODS: In a prospective, randomized, controlled double-blind study, we included 300 patients with severe traumatic pain. They were assigned to 3 groups: Neb10 group received 1 nebulization of 10-mg morphine; Neb20 group received 1 nebulization of 20-mg morphine, repeated every 10 minutes with a maximum of 3 nebulizations; and the IV morphine group received 2-mg IV morphine repeated every 5 minutes until pain relief. Visual analog scale was monitored at baseline, 5, 10, 15, 20, 25, 30, and 60 minutes after the start of drug administration. Treatment success was defined by the percentage of patients in whom visual analog scale decreased greater than or equal to 50% of its baseline value. When this end point was not reached, rescue morphine was administered. Pain resolution time was defined by the elapsed time between the start of the protocol and the reach of treatment success criteria.
RESULTS: Success rate was significantly better at 97% (95% confidence interval [CI], 93-100) for Neb20 group compared to Neb10 group (81% [95% CI, 73-89]) and IV morphine group (79% [95% CI, 67-84]). The lowest resolution time was observed in Neb20 group (20 minutes [95% CI, 18-21]). Side effects were minor and significantly lower in both nebulization groups compared to IV morphine group.
CONCLUSIONS: Nebulized morphine using boluses of 10 mg has similar efficacy and better safety than IV titrated morphine in patients with severe posttraumatic pain. Increasing nebulized boluses to 20 mg increases the effectiveness without increasing side effects.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26143313     DOI: 10.1016/j.ajem.2015.06.014

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  8 in total

1.  Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trail-reply.

Authors:  Fabien Lemoel; Jacques Levraut
Journal:  Intern Emerg Med       Date:  2019-04-17       Impact factor: 3.397

Review 2.  Analgesia in Patients with Trauma in Emergency Medicine.

Authors:  David Häske; Bernd W Böttiger; Bertil Bouillon; Matthias Fischer; Gernot Gaier; Bernhard Gliwitzky; Matthias Helm; Peter Hilbert-Carius; Björn Hossfeld; Christoph Meisner; Benjamin Schempf; Arasch Wafaisade; Michael Bernhard
Journal:  Dtsch Arztebl Int       Date:  2017-11-17       Impact factor: 5.594

Review 3.  Essential pharmacologic options for acute pain management in the emergency setting.

Authors:  David H Cisewski; Sergey M Motov
Journal:  Turk J Emerg Med       Date:  2018-12-10

4.  Comparison of Analgesic Effects of Nebulized Morphine with Fentanyl Transdermal Patch and Oral Methadone for Cancer Patients in Terminal Stages; a Double-blind Randomized Controlled Study.

Authors:  Saeed Majidinejad; Mahdi Ebrahimi; Farhad Heydari; Mahdi Ahmadpour; Mehrdad Esmailian
Journal:  Adv J Emerg Med       Date:  2019-04-30

5.  Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers.

Authors:  Thomas Duflot; Tony Pereira; Marie-Pierre Tavolacci; Robinson Joannidès; Frédéric Aubrun; Fabien Lamoureux; Virginie Eve Lvovschi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-29

Review 6.  Inhaled opioids for cancer pain relief: A narrative review.

Authors:  Magdalena Osowicka; Piotr Janowiak; Agnieszka Gorzewska; Monika Lichodziejewska-Niemierko
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

Review 7.  Commonly used agent for acute pain management of sickle cell anemia in Saudi Emergency Department: A narrative review.

Authors:  Reem A Hejazi; Nameer A Mandourah; Aryaf S Alsulami; Hussain T Bakhsh; Reem M Diri; Ahmad O Noor
Journal:  Saudi Pharm J       Date:  2021-02-16       Impact factor: 4.330

Review 8.  Quo Vadis PCA? A Review on Current Concepts, Economic Considerations, Patient-Related Aspects, and Future Development with respect to Patient-Controlled Analgesia.

Authors:  S Nardi-Hiebl; L H J Eberhart; M Gehling; T Koch; T Schlesinger; P Kranke
Journal:  Anesthesiol Res Pract       Date:  2020-02-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.